A Study of Lirafugratinib in Non-CCA Solid Tumors With FGFR2 Fusion or Rearrangement

Phase 2 — Testing in a larger group (up to a few hundred people) to further evaluate safety and begin to assess effectiveness.

Trial locations(19 sites)

United States

Mayo Clinic, Phoenix, Arizona

Mayo Clinic, Jacksonville, Florida

Moffitt Cancer Center, Tampa, Florida

University of Chicago Medical Center, Chicago, Illinois

Massachusetts General Hospital, Boston, Massachusetts

Mayo Clinic, Rochester, Minnesota

The University of Texas M.D. Anderson Cancer Center, Houston, Texas

France

Institut Bergonie, Bordeaux

Centre Georges François Leclerc, Dijon

Centre Leon Berard, Lyon

Gustave Roussy Cancer Campus, Paris

South Korea

Seoul National University Hospital, Seoul

Samsung Medical Center, Seoul

Spain

START Barcelona-Hospital HM Nou Delfos, Barcelona

Hospital Universitario Fundación Jiménez Díaz- START MADRID, Madrid

Hospital Universitario HM Sanchinarro-START MADRID-CIOCC, Madrid

United Kingdom

University College Hospital (NIHR UCLH Clinical Research Facility), London

Sarah Cannon Research Institute UK, London

The Christie NHS Foundation, Manchester